Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
May 4, 2016 8:50 AM EDT
Piper Jaffray analyst David Amsellem lowered estimates and his price target on Sagent Pharmaceuticals (NASDAQ: SGNT) to $22.00 (from $23.00) but maintained an Overweight rating following Q1 results. While the top lined was pressured, clarity on a deep pipeline is emerging, the analyst said.
Amsellem commented, "Sagent reported 1Q16 EPS of ($0.15) on... More
May 4, 2016 6:47 AM EDT
RBC Capital maintained an Outperform rating on Sagent Pharmaceuticals (NASDAQ: SGNT), and cut the price target to $20.00 (from $28.00), following the company's 1Q earnings report. Weakness in SGNT's anti-infective business is due in part to a weak cold and flu season. This trend will... More
May 3, 2016 7:34 AM EDT
Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q1 EPS of ($0.15), $0.16 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $67.3 million versus the consensus estimate of $74.3 million.
Sagents business plan for fiscal 2016 currently anticipates:
Net...
More
